


rTMS. No significant changes after 1 Hz vermis rTMS may suggest either large distance between the rTMS coil and the vermis or our sample is too small to make definitive conclusions.

Supported by MZ0PCP2005 and 1M0517



P0325

Electroconvulsive therapy in autism: Hope for severe psychopathology

L.E. Wachtel. *Department of Psychiatry, Johns Hopkins School of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA*

Aim: This paper reviews electroconvulsive therapy (ECT) in children and adults with autism and concomitant psychopathology, including affective illness, catatonia and self-injury. Case examples are highlighted.

Method: A review of the English-language literature on ECT in pediatric, adult, autistic and mentally retarded populations was conducted, with focus on catatonia, drug-resistant psychiatric illness and self-injury. This was combined with the author's experience with two autistic adolescents in catatonic stupor, and an autistic child and young adult with severe affective disturbance and self-injury. All four patients underwent ECT with excellent symptom resolution.

Results: ECT is an effective and safe treatment modality across the lifespan for a wide range of psychopathology. Current literature supports the appropriateness, safety and efficacy of ECT in autistic and intellectually disabled populations, where patients suffer from an increased incidence of psychiatric and behavioral disturbances. The following cases are presented:

Pt 1: An 18-year-old female with autism, MR and self-injury in classic catatonic stupor.

Pt 2: A 15 year-old male with autism and MR in catatonic stupor confounded by bradycardia and arrhythmias.

Pt 3: A 19-year-old male with autism, MR, profound depression, tics, compulsions and catatonic symptoms accompanied by self-injury.

Pt 4: An 8-year-old boy with autism, MR, cyclical mood disturbance and intractable self-injury confined to full-body protective equipment.

Conclusion: Electroconvulsive therapy affords excellent symptom remission in autistic individuals with affective illnesses and catatonia, which may be complicated by dangerous self-injury. Prompt diagnosis and pursuit of ECT significantly improve clinical outcome in this patient population.

Poster Session II: Lithium and Other Mood Stabilisers

P0326

Lithium nephropathy in Sweden

H. Bendz¹, S. Schön², M. Aurell³, P.O. Attman³. ¹ *Department of Psychiatry, Lund University Hospital, Lund, Sweden* ² *Department of Internal Medicine, Ryhov County Hospital, Jönköping, Sweden* ³ *Department of Nephrology, Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden*

Background and Aims: Uncertainty prevailing about the role of lithium for the development of chronic renal failure; and the prevalence of lithium-induced end-stage renal disease (ESRD) being virtually unknown, we decided to clarify these issues.

Methods: Using a questionnaire we counted the number of former or present lithium patients among all ESRD patients on renal replacement therapy (RRT, i.e. dialysis or renal transplant) in two defined regions in Sweden, comprising 30 % of 9 million Swedes. We also counted the number of all lithium patients in the areas. A chart review is under way to retrieve clinical data for the assessment of the nephrotoxic effect of the lithium therapy.

Results: There were 2,270 RRT patients (0.08 % of the general population). Twenty-seven of them (1.2 %) acknowledged long-term lithium treatment. Seventeen were on dialysis, ten were transplanted. The concurrent number of lithium patients was 3,567.

Based on our own earlier studies we estimate that 900 (25 %) of the lithium patients in the two regions had been on lithium ≥ 15 years. Thus, twenty-seven of the long-term lithium patients in this study were subject to RRT.

Conclusions: The prevalence of lithium nephropathy in the RRT population is at least 1 %, 0.8 % in the entire lithium population, and approximately 3 % among long-term lithium patients. The risk of developing ESRD is higher when on lithium therapy compared to the general population. Our results so far underscore the need for adequate safety programs, ascertaining the early detection of lithium nephropathy.

P0327

Efficacy of Quetiapine monotherapy in rapid cycling bipolar disorder compared to Sodium Valproate: A pilot study

T. Drieling¹, J.M. Langosch¹, N.C. Biedermann¹, C. Born², J. Sasse³, H. Bauer⁴, J. Walden¹, M. Bauer³, M. Berger¹, H. Grunze². ¹ *Department of Psychiatry, Albert-Ludwigs-University of Freiburg, Freiburg, Germany* ² *Department of Psychiatry, Ludwig-Maximilians-University of Munich, Munich, Germany* ³ *Department of Psychiatry, Carl-Gustav-Carus-University of Dresden, Dresden, Germany* ⁴ *AstraZeneca GmbH, Wedel, Germany*

The aim of this study was to examine the long-term efficacy and safety of a monotherapy with quetiapine or sodium valproate (VPA) in patients with rapid cycling bipolar disorder.

This open-label trial was conducted at three German centers. A sample of 38 remitted or partly remitted bipolar patients with rapid cycling (quetiapine $n = 22$; VPA $n = 16$) were treated with quetiapine or VPA (flexible-dose design) up to 12 months. Analyses were based on the ITT-LOCF principle.

41 % of the patients with quetiapine and 50 % with VPA completed the trial. According to the Clinical Global Impression Scale responder rates tended to be higher for quetiapine than for VPA: i.e. 43 % vs. 25 % (depression), 48 % vs. 36 % (mania), and 43 % vs. 19 % (improvement in both mania and depression). There were no differences found between the treatment groups evaluating the HRSD, MADRS and YMRS. In contrast, Life Chart Method data showed that patients being treated with quetiapine had significantly less depressive days than patients on VPA whilst they did not differ in the number of days with manic symptoms. The incidence of adverse events, especially of orthostatic dysregulation and sedation was higher in the quetiapine group.

Quetiapine may be more effective than VPA regarding depressive symptoms and as effective as VPA in the treatment of manic symptoms in the long-term treatment of rapid cycling bipolar disorder. The side effect profile of quetiapine tends to be less favorable than the one of VPA.

P0328

Hematologic toxicity with Sodium Valproate in bipolar affective disorder and comorbid Behçet's syndrome

I. Kirpinar, E. Yazici, E. Deveci, E. Ozan, N. Aydin. *Department of Psychiatry, Faculty of Medicine Atatürk University, Erzurum, Turkey*

Objectives: Behçet's Disease (BD) is a primary vasculitis with wide variety of symptoms, in which psychiatric disorders as Bipolar Affective Disorder (BPD) are seen. In such cases; as in all comorbidities, the importance of preferring appropriate treatment is emphasized.

We present a case of hematologic toxicity associated with a valproate level of 116 mg/l in of BPD and BD comorbidity.

Case: The 38 years old male patient, who was diagnosed as BPD 10 years ago and BD 3 years ago, was hospitalized for mixed episode with psychotic features. His routine laboratory parameters were in normal ranges. Olanzapine 10mg/d and valproate 500mg/d were started and Valproate was titrated up to 1000 mg/d. At the 8th day of medication he complained of fatigue and somnolence. By the following 6 days a decrease in the hematologic values as: haemoglobin: 15,0/11,4g/dl, hematocrit: %42/32, platelets: 334000/202000 microg/ml was noticed. He had no active symptoms of BD. The liver enzymes were moderately high and because of the hepatotoxicity with valproate was reported in previous studies, Valproate was stopped and Olanzapine was continued. The hematological and biochemical parameters normalized in two weeks.

The decrease of hematological parameters could not be explained by BD itself or any other organic pathology and normalized after cessation of valproate. Thus a hematotoxicity associated by valproate was considered.

Conclusions: Although the effects of the comorbidity of BPD-BD to hemotoxicity are not clear exactly, this case underlies the importance of careful monitoring the Valproate levels and associated parameters in BPD particularly if comorbidity is present.

P0329

Carbamazepine induced bicytopenia, three years later- case report

G. Nikolic-Balkoski, D. Duisin. *CCS Institute of Psychiatry, School of Medicine Belgrade, Belgrade, Serbia and Montenegro*

Carbamazepine was the first anticonvulsant widely used in psychiatry, first for the treatment of bipolar disorder and later for other psychotic disorder (adjunctive). Some of the side effects, which usually occur at the beginning of the therapy with this medicament, are hematological changes which consider transitory leucopenia (10%), persistent leucopenia (2%) and rarely thrombocytopenia. Just these side effects were registered in patient described in this paper.

26 year old men diagnosed as schizophrenia (according to ICD X criteria) was administrated carbamazepine as adjuvant therapy because difficulties in behavior control, seven years ago in dosage of 400mg daily. After four years of therapy, on routine complete blood count (CBC) checking decreased number of white blood cells (2.9 white cells/mm³) and platelets (110000/mm³) were registered. Carbamazepine was excluded from therapy immediately, and from that time on patient is under a regular control of hematologist who diagnosed Bicytopenia (Leucopenia and Thrombocytopenia) and prescribed multivitamin therapy. After three years of these changes, CBC normalized. This entire time patient did not have any symptom which could consider immunological trouble or problem with blood coagulation.

P0330

Psychophysiological and neurobehavioral effects of endogenous Lithium

C.H. Norra¹, J. Feilhauer², G.A. Wiesmueller³, H.J. Kunert⁴.
¹ *Department of Psychiatry, Ruhr-University Bochum, Bochum, Germany* ² *Department of Clinical Psychological Science, Faculty of Psychology, Maastricht University, Maastricht, The Netherlands* ³ *Environmental Specimen Bank for Human Tissue, Westphalian Wilhelms University, Muenster, Germany* ⁴ *Allgemeine Hospitalgesellschaft, Duesseldorf, Germany*

Backgrounds and Aims: Lithium occurs naturally in food and water. While low environmental concentrations in drinking water are associated with mental illnesses and behavioral offences, at therapeutic dosages it is used to treat psychiatric disorders, partly by facilitating serotonergic (5-HT) neurotransmission. However, as little is known about the physiological role of nutritional lithium for neurobiological functioning and emotional processing in the general population, endogenous lithium concentrations were hypothesized to be associated with measurable effects on emotional liability and the loudness dependence (LD) that is proposed one of the most valid indicators of 5-HT neurotransmission.

Methods: Auditory evoked potentials (AEP) of healthy volunteers with either high or low lithium serum concentrations were recorded using multi-channel EEG. Emotional liability was assessed using the Brief Symptom Inventory (BSI).

Results: Serum lithium concentrations varied widely, low levels correlating with symptoms of Somatization. While there were no significant correlations between LD and lithium concentrations, LD correlated positively with Paranoid Ideation, and in the high-lithium group inversely with further aspects of emotional liability (Depression, Psychological Distress).

Conclusions: Effects of low levels of endogenous lithium are associated with an increase in emotional liability, and high levels